Skip to main content

Table 6 Details and outcomes of 6 HBsAg-negative/HBcAb-positive DLBCL patients who developed HBV reactivation after rituximab-containing chemotherapy

From: Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival

Patient no. Age (years) Sex Baseline R-CHOP cycles Interval between last cycle and HBV reactivation (days) At diagnosis of HBV reactivation Outcome
IPI Stage HBeAb ALT (U/L) AST (U/L) TB (μmol/L) Peak HBV DNA (IU/mL) Peak ALT (U/L) Peak AST (U/L) Peak TB (μmol/L)
1 65 Male 4 3 + 18.0 68.2 8.9 5 42 1.72 × 107 333.1 285.8 69.0 Alive and well
2 21 Male 3 3 - 22.0 27.0 36.6 2 24 8.60 × 103 107.6 60.2 47.1 Died of lymphoma
3 69 Female 2 3 - 21.0 25.0 9.4 6 23 1.80 × 105 230.8 120.1 11.0 Alive and well
4 70 Male 3 3 - 10.0 29.0 11.1 7 98 4.76 × 106 239.0 174.0 8.1 Died of lymphoma
5 26 Female 2 3 + 10.0 15.0 6.4 2 27 9.28 × 106 106.0 89.0 7.8 Alive and well
6 68 Male 1 1 - 25.0 35.0 7.0 6 29 4.47 × 104 219.2 204.5 11.3 Alive and well
  1. R-CHOP, cyclophosphamide, hydroxydaunomycin (doxorubicin), vincristine, and prednisone regimen. Other abbreviations as in Tables 1 and 2.